“Creation of a pharmaceutical cluster in Tatarstan has become an essential issue”. The statement was made by Orest Ibragimov, the Director of Nanopharm Development Company, during a press-breakfast held at the “Idea” Technopark.
As “Tatar-Inform” informed, Ibragimov has pointed out that “the republic has gained an exceptionally profound competence in the field of pharmacy with the higher education as a starting point”. Kazan Federal University, possessing research and technology infrastructure related to pharmaceutical development, was referred to as a high-end example. According to the expert, “Tatchempharmpreparaty” company has made a tremendous breakthrough in terms of re-equipment of its production facilities with the focus on manufacturing of new products.
Tatarstan pharmaceutical market amounts to about 2 per cent of the whole Russian market, which approximates to 26 bln rubles.
“Last year we created a research center which is going to expand for manufacturing of drugs against AIDS and leukemia, medicinal products used at transplantation of organs,” informed Sergey Yushko, the Director of “Idea” Technopark while summing up the results of 2016.
In 2017, the Technopark plans to expand the rate of pharmaceutical development, particularly in the field of biotechnology.
Orest Ibragimov told about short-term plans of his company: “As of now, two medicines are being prepared for manufacturing: the first one is for transplantation of organs and tissues, and the second one – for treatment of chronic myeloid leukemia”.